Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer

• Published in: Radiotherapy and oncology 2014-12, Vol.113 (3), p.331-336
• Main Authors: Koerber, Stefan Alexander, Schoneweg, Clara, Slynko, Alla, Krug, David, Haefner, Matthias F, Herfarth, Klaus, Debus, Juergen, Sterzing, Florian, von Knebel Doeberitz, Magnus, Prigge, Elena-Sophie, Reuschenbach, Miriam
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anus Neoplasms - diagnosis; Anus Neoplasms - mortality; Anus Neoplasms - pathology; Anus Neoplasms - therapy; Anus Neoplasms - virology; Biomarkers, Tumor - analysis; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Carcinoma, Squamous Cell - virology; Chemoradiotherapy - methods; Cyclin-Dependent Kinase Inhibitor p16 - analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Papillomaviridae - isolation & purification; Polymerase Chain Reaction - methods; Prognosis; Survival Rate; Treatment Outcome; Young Adult
• ISSN: 1879-0887
• DOI: 10.1016/j.radonc.2014.11.013

The purpose of this study was to evaluate HPV-DNA and p16(INK4a) (p16) expression as prognostic markers for outcome in patients with anal cancer. From January 2000 to December 2011 a cohort of 105 anal cancer patients was treated with definitive chemoradiation at our institution. Tumor biopsies from 90 patients were analyzed for HPV-DNA by polymerase chain reaction and for p16 expression by immunohistochemistry. Median follow-up was 48.6months (range 2.8-169.1months). HPV-DNA or p16-expression was found in 75 anal cancers each (83.3%), concordance was detectable in 70 tumors (77.8%). Significantly improved overall survival (OS) [77.1% vs. 51.4%, p=0.005], progression-free survival (PFS) [64.0% vs. 35.0%, p